Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H25N3O |
Molecular Weight | 263.3785 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
InChI
InChIKey=VOBHXZCDAVEXEY-JSGCOSHPSA-N
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdfCurator's Comment: description was created based on several sources, including
https://blackpoppymag.wordpress.com/substances/dexedrine-dexamphetamine/
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdf
Curator's Comment: description was created based on several sources, including
https://blackpoppymag.wordpress.com/substances/dexedrine-dexamphetamine/
Amphetamine is also prescribed in enantiopure and prodrug form as dextroamphetamine and lisdexamfetamine respectively. Lisdexamfetamine is structurally different from amphetamine, and is inactive until it metabolizes into dextroamphetamine. Dextroamphetamine is useful for those with ADHD and Narcolepsy. It improves self-control for people who have a hard time naturally controlling themselves. Dextroamphetamine aids a person learning and memory of words, and perhaps makes the brain stronger. When a person given dextroamphetamine is tested, their brain is extremely active in the brain parts required for the test and radically less active in other parts. Short practice sessions with dextroamphetamine have a greater effect on learning than sessions without dextroamphetamine. Dextroamphetamine raises decision-making scores, improves choices, and changes beliefs about rewards; at the same time, dextroamphetamine barely—if at all—affects guesses of time. Those who feel lower amounts of joy from dextroamphetamine have greater impulsivity improvements compared to those who feel extreme happiness. The drug should be avoided for those who have hypersensitivity to amphetamines, a history of drug abuse, cardiovascular diseases, hypertensive disease, hyperthyroidism, or in those with glaucoma. In 1935, the medical community became aware of the stimulant properties of amphetamine, specifically dextroamphetamine, and in 1937 Smith, Kline, and French introduced Dexedrine tablets, under the tradename Dexedrine. In the United States, Dexedrine tablets were approved to treat narcolepsy, attention disorders, depression, and obesity. Dexedrine, along with other sympathomimetic, was eventually classified as schedule II, the most restrictive category possible for a drug with recognized medical uses. The exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). Modulation of serotonergic pathways may contribute to the calming effect.
Originator
Sources: http://adisinsight.springer.com/drugs/800020876http://www.chemeurope.com/en/encyclopedia/dextroamphetamine.html
Curator's Comment: in 1935, the medical community became aware of the stimulant properties of amphetamine, specifically dextroamphetamine, and in 1937 Smith, Kline, and French introduced Dexedrine tablets, under the tradename Dexedrine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0050432 |
|||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17239355 |
|||
Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7751968 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19244097 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date2007 |
|||
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date2007 |
|||
Primary | DEXEDRINE Approved UseNarcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Launch Date1980 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
47.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.6 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
431 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Disc. AE: Irritability, Decreased appetite... AEs leading to discontinuation/dose reduction: Irritability (1.3%) Sources: Page: p.8Decreased appetite (0.86%) Insomnia (0.86%) |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Disc. AE: Delirium, Tachycardia... AEs leading to discontinuation/dose reduction: Delirium (acute) Sources: Page: e771Tachycardia Hypertension Tachypnea Creatine kinase increased (mild) |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Disc. AE: Insomnia, Tachycardia... AEs leading to discontinuation/dose reduction: Insomnia (2%) Sources: Page: p.8Tachycardia (1%) Irritability (1%) Hypertension (1%) Headache (1%) Anxiety (1%) Dyspnea (1%) |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Disc. AE: Ventricular hypertrophy, Tic... AEs leading to discontinuation/dose reduction: Ventricular hypertrophy (1%) Sources: Page: p.8Tic (1%) Vomiting (1%) Psychomotor hyperactivity (1%) Insomnia (1%) Rash (1%) |
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Other AEs: Decreased appetite, Insomnia... Other AEs: Decreased appetite (below serious, 29 patients) Sources: Insomnia (below serious, 7 patients) Weight decreased (below serious, 3 patients) Irritability (below serious, 6 patients) Fatigue (below serious, 4 patients) Nasopharyngitis (below serious, 2 patients) |
20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Nausea... |
50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 4 patients) Sources: Nausea (below serious, 1 patient) Vomiting (below serious, 2 patients) |
70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 2 patients) Sources: Nausea (below serious, 2 patients) |
70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Other AEs: Diarrhea, Dry mouth... Other AEs: Diarrhea (below serious, 6 patients) Sources: Dry mouth (below serious, 25 patients) Fatigue (below serious, 6 patients) Feeling jittery (below serious, 10 patients) Irritability (below serious, 8 patients) Upper respiratory tract infection (below serious, 5 patients) Heart rate increased (below serious, 4 patients) Weight decreased (below serious, 8 patients) Anorexia (below serious, 4 patients) Decreased appetite (below serious, 26 patients) Headache (below serious, 20 patients) Initial insomnia (below serious, 8 patients) Insomnia (below serious, 10 patients) Libido decreased (below serious, 4 patients) Hyperhidrosis (below serious, 5 patients) |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Disc. AE: Abuse, Dependence... AEs leading to discontinuation/dose reduction: Abuse Sources: Page: p.1Dependence Cardiovascular disorder (NOS) (grade 3-5) Stroke (serious) Myocardial infarction (serious) Blood pressure increased Heart rate increased Psychiatric symptom NOS Psychotic symptom Manic symptom Growth suppression Vascular disorders Raynaud's phenomenon Serotonin syndrome |
50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Other AEs: Decreased appetite, Dry mouth... Other AEs: Decreased appetite (below serious, 8 patients) Sources: Dry mouth (below serious, 7 patients) Insomnia (below serious, 10 patients) Irritability (below serious, 3 patients) Diaphoresis (below serious, 2 patients) Libido decreased (below serious, 2 patients) Tinnitus (below serious, 2 patients) Muscle tension (below serious, 4 patients) Tachycardia (below serious, 3 patients) Paresthesia (below serious, 2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Decreased appetite | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Insomnia | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Irritability | 1.3% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Hypertension | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Tachycardia | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Tachypnea | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Delirium | acute Disc. AE |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Creatine kinase increased | mild Disc. AE |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Anxiety | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Dyspnea | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Headache | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Hypertension | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Irritability | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Tachycardia | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Insomnia | 2% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Insomnia | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Psychomotor hyperactivity | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Rash | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Tic | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Ventricular hypertrophy | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Vomiting | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Nasopharyngitis | below serious, 2 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Decreased appetite | below serious, 29 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Weight decreased | below serious, 3 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Fatigue | below serious, 4 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Irritability | below serious, 6 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Insomnia | below serious, 7 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Nausea | below serious, 1 patient | 20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Nausea | below serious, 1 patient | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Vomiting | below serious, 2 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Headache | below serious, 4 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Headache | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Nausea | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Feeling jittery | below serious, 10 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Insomnia | below serious, 10 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Headache | below serious, 20 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Dry mouth | below serious, 25 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Decreased appetite | below serious, 26 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Anorexia | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Heart rate increased | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Libido decreased | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Hyperhidrosis | below serious, 5 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Upper respiratory tract infection | below serious, 5 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Diarrhea | below serious, 6 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Fatigue | below serious, 6 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Initial insomnia | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Irritability | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Weight decreased | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Abuse | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Blood pressure increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Dependence | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Growth suppression | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Heart rate increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Manic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Psychiatric symptom NOS | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Psychotic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Raynaud's phenomenon | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Serotonin syndrome | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Vascular disorders | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Cardiovascular disorder (NOS) | grade 3-5 Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Myocardial infarction | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Stroke | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Insomnia | below serious, 10 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Diaphoresis | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Libido decreased | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Paresthesia | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Tinnitus | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Irritability | below serious, 3 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Tachycardia | below serious, 3 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Muscle tension | below serious, 4 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Dry mouth | below serious, 7 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Decreased appetite | below serious, 8 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
Page: 7, 78 |
no [Inhibition 87.3 uM] | |||
Page: 7, 78 |
no [Inhibition 89 uM] | |||
Page: 7, 78 |
no [Inhibition 90 uM] | |||
Page: 7, 78 |
no [Inhibition 90.8 uM] | |||
Page: 7, 78 |
no [Inhibition 92.1 uM] | |||
Page: 7, 78 |
no [Inhibition 92.5 uM] | |||
Page: 7, 78 |
no [Inhibition 94.2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
likely | likely (co-administration study) Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE; Page: 4.0 |
||
Page: 21.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of amphetamine on the expression of the metabotropic glutamate receptor 5 mRNA in developing rat brain. | 2000 Dec |
|
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study. | 2001 |
|
Anorectic drugs and pulmonary hypertension from the bedside to the bench. | 2001 Apr |
|
Effect of 6-hydroxydopamine or repeated amphetamine treatment on mesencephalic mRNA levels for AMPA glutamate receptor subunits in the rat. | 2001 Apr 20 |
|
Nicotine sensitization increases dendritic length and spine density in the nucleus accumbens and cingulate cortex. | 2001 Apr 27 |
|
Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. | 2001 Apr 27 |
|
Neural mechanisms of motion sickness. | 2001 Feb |
|
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat. | 2001 Jun 1 |
|
Analysis of amphetamine and congeners in illicit samples by liquid chromatography and capillary electrophoresis. | 2001 Mar |
|
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. | 2001 May |
|
Amphetamine normalizes the electrical activity of dopamine neurons in the ventral tegmental area following prenatal ethanol exposure. | 2001 May |
|
Chronic amphetamine exposure during the preweanling period does not affect avoidance learning or novelty-seeking of adult rats. | 2001 May |
|
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. | 2001 May 1 |
|
Genes in drug abuse. | 2001 May 1 |
|
Post-training injections of catecholaminergic drugs do not modulate fear conditioning in rats and mice. | 2001 May 4 |
|
Lisdexamfetamine. | 2007 |
|
An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. | 2007 Jan |
|
Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule. | 2007 May 3 |
|
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. | 2007 Nov 1 |
|
Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician. | 2008 |
|
Lisdexamfetamine: a prodrug stimulant for ADHD. | 2008 Aug |
|
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. | 2008 Jan |
|
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. | 2008 Jan 8 |
|
Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine. | 2008 Jul |
|
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. | 2008 Mar |
|
Lisdexamfetamine dimesylate for childhood ADHD. | 2008 May |
|
Attention-deficit-hyperactivity disorder and reward deficiency syndrome. | 2008 Oct |
|
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. | 2008 Sep |
|
Alopecia following initiation of lisdexamfetamine in a pediatric patient. | 2009 |
|
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine. | 2009 |
|
Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. | 2009 |
|
Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. | 2009 Apr |
|
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. | 2009 Aug 3 |
|
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. | 2009 Dec |
|
Case histories in pharmaceutical risk management. | 2009 Dec 1 |
|
An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. | 2009 Jun |
|
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. | 2009 Jun |
|
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. | 2009 Jun 9 |
|
Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder. | 2009 Nov 15 |
|
Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults. | 2009 Oct |
|
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. | 2010 |
|
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. | 2010 Dec |
|
Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. | 2010 Jun |
|
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. | 2010 Jun 24 |
|
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. | 2010 Jun 24 |
|
New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children. | 2010 May 25 |
|
Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. | 2010 Nov |
|
Use of psychostimulants in patients with dementia. | 2010 Oct |
|
Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? | 2010 Sep |
Sample Use Guides
Attention-deficit/hyperactivity disorder: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg at weekly intervals until optimal response is obtained; maximum: 70 mg/day.
Binge eating disorder: Initial: 30 mg once daily in the morning; may titrate in increments of 20 mg at weekly intervals to target dose of 50 to 70 mg once daily (maximum: 70 mg/day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17035599
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Incubation of lisdexamfetamine in microsomal suspensions at concentrations ranging from 0.01 to 100 M showed no concentration-dependent inhibition for any of the isoenzymes under investigation (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, CYP3A4).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175739
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
NDF-RT |
N0000175729
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
DEA NO. |
1205
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
WHO-ATC |
N06BA12
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
WHO-VATC |
QN06BA12
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
||
|
LIVERTOX |
562
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11597698
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
H645GUL8KJ
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
DB01255
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
C75114
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
7213
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
700810
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
m6841
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB32170
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
100000124476
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
LISDEXAMFETAMINE
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
8690
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
4135
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
Lisdexamfetamine
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
DTXSID00209652
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
608137-32-2
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201222
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY | |||
|
H645GUL8KJ
Created by
admin on Fri Dec 15 16:13:25 GMT 2023 , Edited by admin on Fri Dec 15 16:13:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD